TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07559175: A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.

Sponsor: Aimmune Nestlé Health Science US R&D, LLC · Phase: PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 66 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,965,500

Rescue Site Savings

+$2,626,500

Unlock Full NCT07559175 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07559175 Rescue Dossier →